Graphene-based Biosensor could diagnose lung cancer early
The device, described in the journal Nanoscale, displays the potential to identify specific lung cancer markers at the earliest possible stage. It will be both cost-effective and highly beneficial for health service providers worldwide, researchers said.
London: Scientists have developed a graphene-based biosensor that could 'sniff' out evidence of lung cancer from a person's breath, paving the way for low-cost, early diagnosis systems. Researchers from the University of Exeter in the UK developed a new technique that could create a highly sensitive graphene biosensor with the capability to detect molecules of the most common lung cancer biomarkers.
The new biosensor design could revolutionise existing e-nose devices, that identify specific components of a specific vapour mixture -- for example a person's breath -- and analyses its chemical make-up to identify the cause. The device, described in the journal Nanoscale, displays the potential to identify specific lung cancer markers at the earliest possible stage. It will be both cost-effective and highly beneficial for health service providers worldwide, researchers said.
"The new biosensors which we have developed show that graphene has significant potential for use as an electrode in e-nose devices," said Ben Hogan, a postgraduate researcher from the University of Exeter. "For the first time, we have shown that with suitable patterning graphene can be used as a specific, selective and sensitive detector for biomarkers," Hogan said.
"We believe that with further development of our devices, a cheap, reusable and accurate breath test for early-stage detection of lung cancer can become a reality," he said. The quest to discover viable new techniques to accurately detect early-stage lung cancer is one of the greatest global health care challenges.
Although it is one of the most common and aggressive cancers, killing around 1.4 million people worldwide each year, the lack of clinical symptoms in its early stages means many patients are not diagnosed until the later stage, which makes it difficult to cure.
Due to the unrestrainable nature of the abnormal cancer cells, while they begin in one or both lungs, they are prone to spread to other parts of the body rapidly. There are currently no cheap, simple, or widely available screening methods for early diagnosis of lung cancer.
Using multi-layered graphene, the team suggest that current e-nose devices -- which combine electronic sensors with mechanisms for pattern recognition, such as a neural network -- could revolutionise breath diagnostic techniques.
Using patterned multi-layered graphene electrodes, the team were able to show greater sensing capabilities for three of the most common lung-cancer biomarkers -- ethanol, isopropanol and acetone -- across a range of different concentrations.
The team believes this could be the first step towards creating new, improved and cheaper e-nose devices that could give the earliest possible lung-cancer diagnosis.
Also Read: Novartis study shows skin cancer combo also works on the lungs